Short answer
RET C609Y and C618R are specific RET variants that may appear in MEN2A or familial medullary thyroid cancer discussions when they are confirmed as germline pathogenic or likely pathogenic variants. The report should be interpreted by exact notation, classification, sample type, family history, thyroid and calcitonin context, adrenal and parathyroid screening, and whether relatives need targeted testing.
How to frame the report
| Report clue | Common next question | Why it matters |
|---|---|---|
| C609Y or C618R in germline testing | Was the classification pathogenic or likely pathogenic? | Classification drives family and surveillance questions. |
| Variant found on tumor sequencing | Was confirmatory germline testing considered? | Tumor-only results can have different implications. |
| Known family variant | Are relatives getting targeted testing? | Cascade testing should match the exact family variant. |
GeneReviews, NCI, and MedlinePlus all frame RET/MEN2 as inherited risk conditions where the exact result drives cascade testing. A family plan works best when it gives relatives just enough detail to move from confusion to action.
Why exact notation matters
Codon labels are convenient for conversation, but they can hide details that matter. A report may list C609Y or C618R, but the exact amino acid change, sample type, and classification determine whether the result is suitable for family testing and endocrine follow-up.
That is especially important when the report is being used to guide thyroid planning, pediatric timing, or whether relatives should be offered targeted testing.
What the result can change
- Whether the family has a clearly actionable MEN2A or FMTC result
- Whether children or siblings need targeted cascade testing
- Whether endocrine follow-up should be coordinated sooner
- Whether a VUS should be treated as unresolved rather than actionable
NCI's childhood MEN2 guidance makes it clear that early detection can affect management. That means the exact report language matters before anyone assumes the codon label alone is enough.
Questions to ask
- Does the report list cDNA and protein notation, such as p.Cys609Tyr or p.Cys618Arg?
- Was the result from blood, saliva, tumor tissue, or paired tumor-normal testing?
- Does the report call the variant pathogenic, likely pathogenic, uncertain, or something else?
- Who is coordinating MEN2 endocrine genetics, family testing, and age-specific follow-up?
What the result still cannot prove
A RET codon result can support MEN2 counseling, but it does not by itself prove family-wide risk, the right surveillance schedule, or whether a tumor-only finding should be treated as inherited without the rest of the report.
FAQ
What do C609Y and C618R usually mean on a RET report?
They are specific RET variants that can appear in MEN2A or familial medullary thyroid cancer contexts when confirmed as germline pathogenic or likely pathogenic variants.
Why is exact notation important?
The report should be read by exact notation, classification, sample type, family history, and clinical context rather than by codon label alone.
Does a tumor-only RET result count as inherited risk?
No. A tumor-only finding is not the same as a confirmed inherited result and usually needs germline follow-up if inherited risk is the question.
What if the variant is classified as uncertain?
An uncertain variant should be handled differently from a clearly pathogenic or likely pathogenic germline result, especially before family testing decisions are made.
Should relatives get targeted testing?
If a familial pathogenic or likely pathogenic RET variant is confirmed, relatives usually need targeted testing for that exact variant, not just a broad RET panel.
When should clinicians ask for more detail?
When the report only gives a codon or variant shorthand, when the sample type is unclear, or when the family plan still needs MEN2A coordination.
Related guides: RET codon 609, 611, 618, and 620 questions, RET negative family variant testing interpretation, RET cascade testing for children questions, and RET tumor testing vs germline testing.